Percutaneous coronary intervention strategies and prognosis for graft lesions following coronary artery bypass grafting

Experimental and Therapeutic Medicine

Volumn 9, Issue 5, 2015, Pages 1656-1664

  Liu, Yin ^a   Zhou, Xiu Jun ^a   Jiang, Hua ^a   Gao, Ming Dong ^a   Wang, Lin ^a   Shi, Yutian ^a   Gao, Jing ^a  

^a Tianjin Chest Hospital   (China)

Author keywords

Coronary artery bypass grafting; Follow up; Multivariate risk factors; Percutaneous coronary intervention; Prognosis

Indexed keywords

FIBRINOGEN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTICOAGULATION; ARTICLE; BARE METAL STENT; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE NECROSIS; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RETROSPECTIVE STUDY; REVASCULARIZATION; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; SURVIVAL RATE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 84925209291     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2366     Document Type: Article

References (33)

1. Lee MS, Park SJ, Kandzari DE, et al: Saphenous vein graft intervention. JACC Cardiovasc Interv 8: 831-843, 2011.
2. Campeau L, Enjalbert M, Lespérance J, Vaislic C, Grondin CM and Bourassa MG: Atherosclerosis and late closure of aortocoronary saphenous vein grafts: Sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 68: II1-II7, 1983.
3. Fitzgibbon GM, Leach AJ, Kafka HP and Keon WJ: Coronary bypass graft fate: longerm angiographic study. J Am Coll Cardiol 17: 1075-1080, 1991.
4. Weintraub WS, Jones EL, Craver JM and Guyton RA: Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol 73: 103-112, 1994.
5. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, et al; VA Cooperative Study Group #207/297/364: Long-term patency of saphenous vein and left internal mammary artery grafts after coronary bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 44: 2149-2156, 2004.
6. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD and Burton JR: Coronary bypass graft fate and patient outcome: angiographie follow-up of 5, 065 grafts related to survival and reoperation in 1, 388 patients during 25 years. J Am Coll Cardiol 28: 616-626, 1996.
7. Eagle KA, Guyton RA, Davidoff R, et al; American College of Cardiology; American Heart Association: ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 110: e340-e437, 2004.
8. Baim DS: Percutaneous treatment of saphenous vein graft disease: The ongoing challenge. J Am Coll Cardiol 42: 1370-1372, 2003.
9. Baldwin DE, Abbott JD, Trost JC, et al: Comparison of drug-eluting and bare metal stents for saphenous vein graft lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 106: 946-951, 2010.
10. Gyenes G, Norris CM, Graham MM; APPROACH Investigators: Percutaneous revascularization improves outcomes in patients with prior coronary artery bypass surgery. Catheter Cardiovasc Interv 82: E148-E154, 2013.
11. Hiscock M, Oqueli E and Dick R: Percutaneous saphenous vein graft intervention-a review. Heart Lung Circ 16: S51-S55, 2007.
12. Sabik JF III, Blackstone E, Gillinoy M, Smedira NG and Lytle BW: Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation 114: I454-I460, 2006.
13. Pucelikova T, Mehran R, Kirtane A, et al: Short-and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. Am J Cardiol 101: 63-68, 2008.
14. Meliga E, García-García H, Kukreja N, et al: Chronic total occlusion treatment in post-CABG patients: Saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era. Catheter Cardiovasc Interv 70: 21-25, 2007.
15. Hoffmann R, Hamm C, Nienaber CA, et al; German Cypher Registry: Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels. Coron Artery Dis 18: 559-564, 2007.
16. Vermeesch P, Agostoni P, Verheye S, et al; DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators: Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 50: 261-267, 2007.
17. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, et al: A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 53: 919-928, 2009.
18. Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators: Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371: 2155-2166, 2014.
19. Morrison DA, Sethi G, Sacks J, et al; Investigators of the Department of Veterans Affairs Cooperative Study #385, angina With Extremely Serious Operative Mortality Evaluation (AWESOME): Percutaneous coronary interventions versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass. The VA AWESOME Multicenter Registry: Comparison With the Randomized Clinical Trial. J Am Coll Cardiol 39: 266-273, 2002.
20. Yap CH, Sposato L, Akowuah E, et al: Contemporary results show repeat coronary artery bypass grafting remains a risk factor for operative mortality. Ann Thorac Surg 87: 1386-1391, 2009.
21. Runyan D, Gorges R, Feldman D, McCullough PA, David S and Saba S: Long-term follow-up of lesion-specific outcomes comparing drug-eluting stents and bare metal stents in diseased saphenous vein grafts. Rev Cardiovasc Med 14: 1-6, 2013.
22. Gupta S and Cigarroa JE: The quest for optimal interventional strategy in saphenous vein graft interventions-are we there yet? Catheter Cardiovasc Interv 80: 1118-1119, 2012.
23. Brilakis ES, Rao SV, Banerjee S, et al: Percutaneous coronaryintervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv 4: 844-850, 2011.
24. Ko DT, Guo H, Wijeysundera HC, Zia MI, Džavík V, Chu MW, et al: Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study. JACC Cardiovasc Interv 4: 965-973, 2011.
25. Hindnavis V, Cho SH and Goldberg S: Saphenous vein graft intervention: a review. J Invasive Cardiol 24: 64-71, 2012.
26. Ho PC, Lee AC and Fortuna R: Drug-eluting stenting of saphenous vein graft versus native coronary artery supplying the same myocardial perfusion territory: a pilot retrospective 3-year follow-up. J Invasive Cardiol 24: 516-520, 2012.
27. de Feyter PJ, van Suylen RJ, de Jaegere PP, Topol EJ and Serruys PW: Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 21: 1539-1549, 1993.
28. Xanthopoulou I, Davlouros P, Tsigkas G, Panagiotou A, Hahalis G and Alexopoulos D: Long-term clinical outcome after percutaneous coronary intervention in grafts vs native vessels in patients with previous coronary artery bypass grafting. Can J Cardiol 27: 716-724, 2011.
29. Leal S, Campante Teles R, Calé R, Sousa PJ, Brito J, Raposo L, et al; ACROSS Registry Investigators: Percutaneous revascularization strategies in saphenous vein graft lesions: long-term results. Rev Port Cardiol 31: 11-18, 2012.
30. Vermeersch P, Agostoni P, et al: Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 48: 2423-2431, 2006.
31. Hakeem A, Helmy T, Munsif S, Bhatti S, Mazraeshahi R, Cilingiroglu M, et al: Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7, 994 patients. Catheter Cardiovasc Interv 77: 343-355, 2011.
32. Lozano I, García-Camarero T, Carrillo P, Baz JA, de la Torre JM, López-Palop R, et al: Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results. Rev Esp Cardiol 62: 39-47, 2009 (In Spanish).
33. Goswami NJ, Gaffigan M, Berrio G, Plessa AL, Pfeiffer AM, Markwell SJ and Mishkel GJ: Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie ‘Real World’ Stent Registry. Catheter Cardiovasc Interv 75: 93-100, 2010.